Last reviewed · How we verify
Pivalexin (cefalexin pivoxil)
Pivalexin (generic name: cefalexin pivoxil) is a drug. It is currently in unknown development.
Pivalexin works by being converted into cefalexin in the body, which then inhibits bacterial cell wall synthesis.
Pivalexin is a small molecule inhibitor of bacterial penicillin-binding protein. It is classified as an inhibitor of the drug class, with a mechanism of action as a bacterial penicillin-binding protein inhibitor.
At a glance
| Generic name | cefalexin pivoxil |
|---|---|
| Therapeutic area | Infectious Disease |
| Phase | unknown |
Mechanism of action
Imagine your body's cells are like buildings. Bacteria are like construction workers that build their own cells. Cefalexin, the active form of pivalexin, is like a construction inspector that stops the bacteria from building their cells, ultimately killing them.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pivalexin CI brief — competitive landscape report
- Pivalexin updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Pivalexin
What is Pivalexin?
How does Pivalexin work?
What is the generic name of Pivalexin?
What development phase is Pivalexin in?
Related
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Infectious Disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing